78Q Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.80 |
| 52 Week High | €21.30 |
| 52 Week Low | €14.95 |
| Beta | 0.18 |
| 11 Month Change | -5.71% |
| 3 Month Change | 14.78% |
| 1 Year Change | 25.71% |
| 33 Year Change | 36.93% |
| 5 Year Change | n/a |
| Change since IPO | 34.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.3% | -1.8% | -0.1% |
| 1Y | 25.7% | -18.5% | 2.4% |
Return vs Industry: 78Q exceeded the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 78Q exceeded the German Market which returned 2.4% over the past year.
Price Volatility
| 78Q volatility | |
|---|---|
| 78Q Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 78Q has not had significant price volatility in the past 3 months.
Volatility Over Time: 78Q's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 165 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.
Philogen S.p.A. Fundamentals Summary
| 78Q fundamental statistics | |
|---|---|
| Market cap | €813.85m |
| Earnings (TTM) | -€6.16m |
| Revenue (TTM) | €24.73m |
33.9x
P/S Ratio-136.0x
P/E RatioIs 78Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78Q income statement (TTM) | |
|---|---|
| Revenue | €24.73m |
| Cost of Revenue | €17.46m |
| Gross Profit | €7.27m |
| Other Expenses | €13.43m |
| Earnings | -€6.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 29.39% |
| Net Profit Margin | -24.91% |
| Debt/Equity Ratio | 3.1% |
How did 78Q perform over the long term?
See historical performance and comparison